市況評論

作者

倪國權先生 (Alex Ni)
助理經理

曾任職鋼材交易員及廣告公司主任,所以特別喜歡研究資源類及消費類股票。歡迎來電賜教或交流心得。
電話:
2280 7366

現代牙科 (3600.HK)

2019年2月19日 星期二 觀看次數999

Stock Commentary                                                                                           Date: 18/2/2019

         

Stock:                                                     Modern Dental Group Limited

Closing price:                                      $1.46 (18/02/2019)

52 weeks range:                                         $1.20 - $2.53

Shares outstanding:                           990,277,000

Market Capitalization:                 HK$ 1.446 Billion

Target Price (12 months):                          No Target (initial coverage)

 

Summary :

This is an initial coverage of Modern Dental Group Limited. The company is dental prosthetic device provider and operates their businesses in various cities across the globe. They have three product lines: Fixed Prosthetic devices, Removable Prosthetic devices and Other Devices such as orthodontic devices, sports guards and anti-snoring devices etc. Fixed Prosthetic device is the main source of revenue of the company and currently, Europe and North America are major markets in contributing the company’s income, while Asian market segment continue to increase due to demand rising demand of dental healthcare.

 

Brief Look of the Company :

  1. Modern Dental Group Limited (the Company) is a global dental prosthetic device provider. Its businesses are across the globe. Listed on the Hong Kong Stock exchange in December 2015, the Company raised approximately HKD 664 million and the fund was used mainly to develop new businesses in oversea and acquire target firms.

The chart below illustrates the Company’s worldwide subsidiaries:

 

Source: Modern Dental 2018 interim report

 

In terms of revenue, both Europe and North America market contributed over 70% of the Company’s revenue in 2018, while Greater China market exhibited the largest growth rate in comparison with other markets. The table below explained the breakdown based on each market in their respective original currency against Hong Kong Dollar:

Source: Modern Dental 2018 interim report

 

  1. There are three main product lines (as categorized by the Company):
  1. Fixed Prosthetic devices such as crowns and bridges. These products target patients with dental problems and require dental surgical procedures to amend.

 b. Removable Prosthetic devices such as removable dentures.

               c. Other Devices such as orthodontic devices, sports guards and anti-snoring devices; also, raw materials, dental equipment and services etc.

 In terms of revenue return, fixed prosthetic devices as well as removable dentures are the major contributors to the Company. The graphs below illustrate the Company’s revenue mix as well as sales volume breakdown:

Source: Modern Dental 2018 interim report

SWOT ANALYSIS:

Strength :

  1. As dental healthcare importance increase, the company is able to capture the market share in dental prosthetic market through horizontal integrations.

Weakness :

  1. Niche market Barrier to entry may not be high.

 

Opportunities :

  1. Dental service in Asian market is growing, especially with aging population. The demand for dental prosthetic device increase.

 

Threat :

  1. Worldwide economic slowdown. Trade war.

 

「註:本人倪國權為證監會持牌人士。截至本評論文章發表日止,本人及/或其有聯繫者並無持有全部提及之証券的所有相關財務權益。」; Or
” I, Ni Kwok Kuen Alex, am a licensed person under the Securities and Futures Commission. Until the date this commentary was published, neither I and/or my affiliates are the beneficiary of the securities mentioned herein or are entitled to any financial interests in relation thereto. “

 

 

 

 

研究報告由輝立証券集團旗下於香港證監會持牌的輝立証券(香港)有限公司及/ 或輝立商品有限公司(“輝立”)所發報。本文所包含的資料均為輝立從相信為準確的來源搜集。輝立對有關報告所引致之任何損失或虧損概不負責。本報告所載的資料只供参考用途,並沒有法律約束力,亦不構成投資建議、邀約、購入、出售任何產品。
投資涉及風險,有可能損失投資本金。你應諮詢專業人士,就本身的投資經驗、財務狀況、個人目標及風險取向,以提供投資意見。各類產品的風險,請參閱本公司網頁 http://www.phillip.com.hk《風險披露聲明》。
輝立(或其僱員) 可能持有本文所述有關的投資產品。此外,輝立(或任何附屬公司)隨時可能替向報告內容所述及的公司提供服務、招攬或業務往來。
以上資料為輝立擁有並受版權及知識產權法保護。除非事先得到輝立明確書面批准,否則不應複製、散播或發佈。
返回頁首
聯絡我們
請即聯絡你的客戶主任或致電我們。
研究部
電話 : (852) 2277 6846
傳真 : (852) 2277 6565
電郵 : businessenquiry@phillip.com.hk

查詢及支援
分行資料
投訴程序
查數網
登入
黃師傅每日講股
研究部快訊
免費訂閱
聯絡我們